

“First International congress of Bioimmunotherapy of cancer

An International multidisciplinary meeting”

Sala Perri, Palazzo della Provincia, Piazza Italia , 89125 Reggio Calabria,

April 12-14 2019

IL CONVEGNO E' RIVOLTO A N. 150 partecipanti PROVENIENZA REGIONALE

PROFESSIONE: MEDICO CHIRURGO

discipline in: ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; ANATOMIA PATOLOGICA; CHIRURGIA GENERALE;
CHIRURGIA TORACICA; DERMATOLOGIA E VENEREOLOGIA; EMATOLOGIA; GENETICA MEDICA; MEDICINA
GENERALE (MEDICI DI FAMIGLIA); MEDICINA INTERNA; ONCOLOGIA; RADIOTERAPIA; UROLOGIA;

PROFESSIONE: INFERMIERE

discipline in: INFERMIERE

PROFESSIONE: BIOLOGO

discipline in: BIOLOGO

PROFESSIONE: FARMACISTA

discipline in: FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE;

Presidente: Dott. Pierpaolo Correale

Rationale

New management strategies and newest treatment modalities are rapidly entering in the clinical practice of cancer patients leading to an unexpected improvement in quality of life and survival. In particular, Clinical development of Small molecules with specific molecular targets, immunological treatments and combined treatments are completely changing the way we see and treat some of the most common malignancies including Non small cell lung cancer, breast cancer, gastroenteric malignancies, genitourinary and gynecological malignancies, and malignant melanoma. However, the correct use of these innovative strategies and treatments requires a specific multi-disciplinary approach, modern management procedures, and a rising knowledge of anticancer pharmacology, cancer- and immune-associated molecular biology, immune-oncology, and radiobiology. This meeting highlights the baseline professional needs for a correct diagnosis, care and treatment of these patients at any stage of disease with a prospect of future directions. An international team of scientist and academics will contribute to enhance the skills of people who



Xenia S.a.s. di Francesca Mazza & C.
87030 RENDE (CS)
Via G. Verdi, 144
P. IVA: 03346870789
e-mail: xeniaeventi@gmail.com

operate in the management of these patients and in the designs of innovative treatment strategies for advanced disease and to define the mechanisms of action and the rationale behind the most innovative strategies.

President: Pierpaolo Correale

Copresidents: Pierosandro Tagliaferri e Pierfrancesco Tassone

Honorary Presidents: Michail Sitkovsky, Luigi Pirtoli, Antonio Giordano, Michele Caraglia,

Scientific Committee: Kwong Yok Tsang, Rocco Giannicola, Pietro del Medico, and Fiorella Guadagni

Scientific Secretary Board: Antonella Falzea, Mariangela Polifrone,

Scientific Secretary Staff: Rita Agostino, Domenico Azzarello, Giuseppe Bellocco, Caterina Giuffrè, Antonino Mafodda, Roberto Maisano, Giovanna Orizzonte, and Vincenzo Panuccio.

Scientific Program

Friday, April, 12th, 2019

8.30 Authority salutation

Vice-Ministro dell'economia, Onorevole Senatore **Massimo Garavaglia**

Autorità regionali

Autorità Città Metropolitana

Direzione Strategica Grande ospedale Metropolitano

Associazione Salus Donna : **Anna Mancuso**

Associazione ARCO: **Francesco Provenzano**

09.30 Introduction: Prof Luigi Pirtoli, Prof Pierosandro Tagliaferri, Dr. Pierpaolo Correale

General session: Standard care and patient management (Lingua ufficiale Italiano) :

Chairmen: **Mario Roselli** and **Sabino de Placido**

9.45 Interrelazione ospedale territorio - **Ettore Jorio**

10.00 Dalle Banche dati alla pratica clinica - **Fiorella Guadagni**

10.15 Il passo dalla diagnosi alla presa in carico della “persona” paziente - **Claudio Verusio**

10.30 Sostenibilità dei nuovi trattamenti, reperimento e razionalizzazione delle risorse - **Salvatore**

Palazzo

10.45 Il consenso informato: tutela del paziente o difesa del medico - **Giovanna Chiappetta**

11.00 Le collaborazioni internazionali; formazione e leadership - **Antonio Giordano**

11.15 Riorganizzazione della rete radioterapica regionale - **Stefano Magrini**

11.45 Un modello di integrazione multi-disciplinare complessa nella diagnosi e cura del melanoma maligno; *target therapy* e *immunocheckpoint* - **Giovanna Malara**

12.00 Organizzazione, attrezzatura e necessità irrinunciabili per la creazione di una lung unit efficiente - **Rocco Giannicola**

12.15 Una forza nazionale integrata contro il carcinoma polmonare - **Antonio Santo**

12.30 L’Oncologia nel paziente anziano - **Guido Francini**

12.45 Il ruolo della medicina di precisione nella pratica oncologica - **Vaccarella**

Lunch

Bio-immunotherapy congress (lingua inglese)

Work Opening: **Luigi Pirtoli, Piersandro Tagliaferri, Pierpaolo Correale** ,

I Session – Advancement for Genitourinary Malignancies

Chairmen: **A Madan Ravi , Guido Francini**

15.00 Hormonal therapy evolution in prostate cancer - **Francesco Grillone**

15.15 Role of chemotherapy in prostate cancer - **Edoardo Francini**

15.30 Salvage radiotherapy for prostate cancer; potential predictive immunological parameters of response - **Paolo Tini**

15.45 Kidney Cancer molecular definition, inheritance and treatment implications - **Camillo Porta**

16.00 TKI, mTOR inhibitors and anti-angiogenic mAbs in kidney cancer - **Giacomo Carteni**

16.15 Kidney cancer a long lasting model for cancer immunotherapy: from the interleukin 2 to the immune-check point inhibitors - **Rita Agostino**

16.30 Chemotherapy or immune-check point blockade in the savage treatment of metastatic urological malignancies - **Antonino Mafodda**

16.45 Immuno-oncological treatments for prostate carcinoma future directions - **A. Madan Ravi**

II Active specific Immunotherapy and immune-checkpoint inhibitors in Malignant melanoma, and Head and Neck Carcinoma (HNC)- Chairman: **Stefano Magrini – Marco Merlano**

17.00 Viral infections and HNC: Risks and perspectives - **Grazia Cusi**

17.15 Combined treatments for locally advanced head and neck cancer: the changing role of cetuximab and the new research avenues - **Marta Maddalo**

17.30 Development of Target therapy in the treatment of malignant melanoma - **Michele Del Vecchio INT**

17.45 Immuno-check point inhibitors in the treatment of malignant melanoma: the state of art - **Paola Queirolo**

18.00 Vaccine and adoptive therapy in HNC - **Paolo Pedrazzoli**

18.15 Immunotherapy, immune-checkpoint and combined treatment for HNC - **Marco Merlano**

18.30 Radiological evaluation of Head and neck cancer and malignant melanoma patients receiving Immunological treatments - **Carmen Tebala**

Conclusions of the day

20.30 Dinner

SATURDAY , APRIL 13th, 2019

III Immuno-oncological development and controversies (II)

Chairmen: **Jay Berzowsky and Michail Sitkovsky**

8.30 Critical role of hypoxia and cancer associated inflammation - **M Sitkovsky**

8.45 Animal models and immunolo-oncological research - **Robert M Hoffman**

9.00 Basic principles of immunotherapy, cancer vaccines, co-accessory molecules - **Jack Greiner**

9.15 Active specific immunotherapy Translation from mice to human clinical trials - **Jay Berzowsky**

9.30 Combinational immunological strategies for prostate cancer - **James Gulley**

9.45 History and clinical development of therapeutic immune-checkpoint blockades; future challenges - **Massimo Di Maio**

10.00 Endoplasmic stress as a new target for anticancer therapies and immunological treatments - **Vincenzo Desiderio**

10.15 Interplay between Fc domain of therapeutic antibodies and specific receptors on different effector populations - **Fabio Malavasi**

10.30 Mechanism of failure of immune-checkpoints: effector failure or tumor resistance? - **Claudio Tripodo**

10.45 There still a role for cancer vaccine? **K kosmatpoulos**

11.00 Chemokine receptors enable adoptive T cell therapy homing into solid tumors - **Bruno Cadilha**

11.15 Immunomodulation in cancer beyond PD-1 and PD-L1 - **Sonia Quaratino**

11.30 The new generations of immunecheckpoint inhibitors - **Takuia Tsunoda**

11.45 PD-1 blockade: Antigen cascade, Autoimmunity and Major Histocompatibility Complex - **Pierpaolo Correale**

Coffee break

IV Immuno-oncological development and controversies (neoantigens, immunopriming and monoclonal antibodies)

Cheirmen: **Kwong Yok Tsang and Fabio Malavasi**

12.00 Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Human Malignancies - **Pierfrancesco Tassone**

12.15 Mechanisms of action of a neoantigen-targeting antibody NEO-201 - **Kwong Yok Tsang**

12.30 ADCC : from bench to bedside - **Alfredo Colombo**

12.45 An IL-15 superagonist, ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) elicited by the novel monoclonal antibody NEO-201 against human carcinoma cells - **Massimo Fantini**

13.00 Immunotherapy in the treatment of gynecological malignancies - **Christina Messineo Annunziata/NCI**

13.15 New moAbs in the treatment of acute leukemia - **Caterina Alati**

13.30 New antibodies in the treatment of bilio-pancreatic cancer - **Phil Arlen**

13.45 Lunch

V Lung Cancer Piero Paladini – Baldo Mondello

14.30 Role of surgery and combined approach: neoadjuvant chemoradiotherapy and radio-immunotherapy - **Luca Luzzi**

14.45 Role of the pathologist - **Cristiana Bellan**

15.00 Liquid biopsy and precision medicine - **Marta Castiglia**

15.15 Target therapy on drivers mutations - **Nadia Pasinetti**

15.30 Targeting EGFR pathway as treatment of non small cell lung cancer - **Roberto Bianco**

15.45 New targets for non small cell lung cancer - **Rita Chiari**

16.00 The Advent of immunotherapy from now to the future - **Vito Barbieri**

16.15 Care and monitoring of NSCLC patient in treatment with immune-checkpoint blockade: irAEs Pain, Emesis, Infection, and quality of life - **Rocco Giannicola**

16.30 Radiotherapy, new perspective and immunobiological effects - **Pierpaolo Pastina**

16.45 Immune-checkpoint blockade Response evaluation by Digital analysis - **Valerio Nardone**

17.00 Radiological and clinical evaluation of Lung Cancer patients treated with immunotherapy or target therapy - **Luca Volterrani**

VI Immuno-oncological development and controversies on adoptive therapy and micro RNA

Chairmen. **Massimo Martino and Bruno Martino**

17.15 Donor lymphocyte infusions in AML and MDS? - **Massimo Martino**

17.30 Processing CSE toward Jacie accreditation - **Giulia Pucci**

17.45 T cell therapy for viral infections - **Patrizia Comoli**

18.00 Immunobiological characterization of Tumor infiltrating lymphocytes derived from multiple myeloma patients - **Ciro Botta**



Xenia S.a.s. di Francesca Mazza & C.
87030 RENDE (CS)
Via G. Verdi, 144
P. IVA: 03346870789
e-mail: xeniaeventi@gmail.com

18.15 Car-T based immunotherapy and adoptive therapy - **Marco Rossi**

18.30 Micro-RNAs and long non coding RNAs loops in human cancers: a new deal in anti-cancer treatment and immunotherapy - **Michele Caraglia**

Take the message round table.

Discussion Leaders : **Prof Pierosandro Tagliaferri** and **M Sitkovsky**

SUNDAY , APRIL 14th, 2019

VII Advancement in Gastro-enteric malignancies

Chairmen: **Antonio Russo– Gianfranco Filippelli**

9.00 Anti-angiogenic treatments in gastro-enteric malignancies - **Candida Mastroianni**

9.15 Role and evaluation of microsatellite instability - **Stefano Lazzi**

9.30 Effects of inflammatory status and k-ras mutation on patients response to the thymidylate synthase poly-epitope peptide vaccine - **Pierpaolo Pastina**

9.45 Immune-check point blockade and EGFR inhibition in advanced colorectal cancer; present and future directions - **Teresa Troiani**

10.00 Chemo-immunotherapy of Colorectal cancer; fifteen years of GOLFIG experience – **Pierosandro Tagliaferri**

VIII session – Advancement in gynecological malignancies and breast cancer

Chairmen: **Sandro Pignata and Serafino Conforti**

10.15 Surgery and combined therapeutic approaches to ovary and endometrial cancer - **Stefano Palomba**

10.30 From the anti-blastic drugs to PARP inhibitor - **Sandro Pignata**

10.45 Chemo-immunological treatments of gynaecological malignancies - **Pietro del Medico**

11.00 New pathways for breast cancer treatment; from bench to the bedside and vice-versa - **Paolo Vignieri**

11.30 A critical role for genetists and BRCA mutations - **Manuela Priolo**

11.15 Radiotherapy and Cervical carcinoma, role of integrated treatments - **Carmelo Tuscano**

11.45 The unstoppable advent of cycline inhibitors - **Roberto Maisano**



Xenia S.a.s. di Francesca Mazza & C.
87030 RENDE (CS)
Via G. Verdi, 144
P. IVA: 03346870789
e-mail: xeniaeventi@gmail.com

12.00 PDL-1 blockade in the treatment of triple negative breast cancer - **Francesca Di Rella**

12.15 The new directions of cycline inhibitors - **Michele Caruso**, Humanitas Catania

Congress conclusions and salutations: **Michail Sitkovsky, Pierosandro Tagliaferri, Pierpaolo Correale**